Panchapakesan U, Pollock C A, Chen X M
Department of Medicine, The University of Sydney, Renal Research Group, Kolling Institute of Medical Research, Royal North Shore Hospital, New South Wales 2065, Australia.
Am J Physiol Renal Physiol. 2004 Sep;287(3):F528-34. doi: 10.1152/ajprenal.00445.2003. Epub 2004 Apr 27.
Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) are ligand-activated transcription factors that regulate cell growth, inflammation, lipid metabolism, and insulin sensitivity. PPAR-gamma in the human kidney has been described. However, the role of PPAR-gamma in proximal tubular cells with respect to cell growth and inflammation in diabetic nephropathy is largely unknown. We evaluated the effect of high (30 mM) D-glucose, thiazolidinedione pioglitazone (10 microM), and the selective PPAR-gamma agonist L-805645 (8 microM) on PPAR-gamma expression, growth, and inflammatory parameters in the proximal tubular model of HK-2 cells. PPAR-gamma was present in HK-2 cells and upregulated with 30 mM D-glucose to 177 +/- 31.2% of control (P < 0.05). PPAR-gamma activation was induced by pioglitazone to a similar level to that observed by exposure to high glucose but maximally induced by the selective agonist L-805645. However, L-805645 reduced cell viability in both 5 and 30 mM d-glucose to 73.8 +/- 3.1 and 77.6 +/- 1.4% of control (both P < 0.0001). In parallel, thymidine incorporation was reduced with L-805645 in both 5 and 30 mM D-glucose to 33.3 +/- 3.4 and 37.9 +/- 2.2%, respectively (both P < 0.0001). Flow cytometry demonstrated increased apoptosis and G(1) phase arrest in association with an increase in p21(cip1/waf1) in cells exposed to L-805645. Exposure to 30 mM D-glucose did not significantly change AP-1 promoter activity (89.0 +/- 5.5% of control); however, the addition of L-805645 significantly reduced it to 62.2 +/- 2.7% of control (P < 0.0001). Thirty nanomolar D-glucose induced transforming growth factor-beta(1) to 137.7 +/- 16.9% of control (P < 0.05), and L-805645 was able to suppress this to 68.7 +/- 5.7% of control (P < 0.01 vs. d-glucose). Exposure to 30 mM D-glucose reduced monocyte chemoattractant protein 1 levels to 78.6 +/- 7.1% (P < 0.05) of control, with the reduction more marked in the presence of either pioglitazone (P < 0.01) or L-805645 (P < 0.01). In summary, high glucose upregulates PPAR-gamma and when significantly induced demonstrates anti-proliferative and anti-inflammatory effects.
过氧化物酶体增殖物激活受体γ(PPAR-γ)是配体激活的转录因子,可调节细胞生长、炎症、脂质代谢和胰岛素敏感性。人类肾脏中的PPAR-γ已被描述。然而,PPAR-γ在糖尿病肾病近端肾小管细胞中对于细胞生长和炎症的作用在很大程度上尚不清楚。我们评估了高浓度(30 mM)D-葡萄糖、噻唑烷二酮类药物吡格列酮(10 μM)以及选择性PPAR-γ激动剂L-805645(8 μM)对HK-2细胞近端肾小管模型中PPAR-γ表达、生长和炎症参数的影响。HK-2细胞中存在PPAR-γ,30 mM D-葡萄糖可使其上调至对照的177±31.2%(P<0.05)。吡格列酮诱导PPAR-γ激活至与高糖暴露相似的水平,但选择性激动剂L-805645诱导作用最强。然而,L-805645在5 mM和30 mM D-葡萄糖条件下均将细胞活力降低至对照的73.8±3.1%和77.6±1.4%(均P<0.0001)。同时,L-805645在5 mM和30 mM D-葡萄糖条件下分别将胸苷掺入量降低至33.3±3.4%和37.9±2.2%(均P<0.0001)。流式细胞术显示,暴露于L-805645的细胞中凋亡增加且G1期阻滞,同时p21(cip1/waf1)增加。暴露于30 mM D-葡萄糖并未显著改变AP-1启动子活性(为对照的89.0±5.5%);然而,添加L-805645可使其显著降低至对照的62.2±2.7%(P<0.0001)。30 nM D-葡萄糖将转化生长因子-β1诱导至对照的137.7±16.9%(P<0.05),而L-805645能够将其抑制至对照的68.7±5.7%(与D-葡萄糖相比,P<0.01)。暴露于30 mM D-葡萄糖使单核细胞趋化蛋白1水平降低至对照的78.6±7.1%(P<0.05),在吡格列酮(P<0.01)或L-805645(P<0.01)存在时降低更为明显。总之,高糖上调PPAR-γ,当被显著诱导时表现出抗增殖和抗炎作用。